Results from registered ongoing studies and other publications will be reviewed periodically to evaluate their potential to impact on the recommendations in this guideline. Table 17 continued on following page methods for guideline development evidence base and the judgments supporting the recommen- dation. This is followed by a narrative in support of the rationale. In relevant sections, research recommendations suggest future research to resolve current uncertainties. Comparison with other guidelines We tabulated recommendations from other key English- language guidelines pertinent to the use of blood-pressure lowering agents in individuals with CKD (Table 16). This served to inform topic selection and scope. Also, after recommendations had been drafted, the Work Group reviewed them in the context of the existing guideline recommendations to avoid unnecessary or unwarranted discrepancies. Limitations of approach Although the literature searches were intended to be comprehensive, they were not exhaustive. MEDLINE was the only database searched. Hand searches of journals were not performed, and review articles and textbook chapters were not systematically searched. However, important studies known to domain experts that were missed by the electronic literature searches were added to retrieved articles and reviewed by the Work Group. Review of guideline development process Several tools and checklists have been developed to assess the quality of the methodological process for guideline develop- ment. These include the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria,446 the Conference on Guideline Standardization (COGS) checklist,447 and the Institute of Medicine s recent Standards for Systematic and Clinical Practice Guideines We Can Trust.449 Table 17 and Supplementary Appdenix 2 online show, respectively, the COGS criteria and the Institute of Medicine standards, and how each one of them is addressed in this Guideline. SUPPLEMENTARY MATERIAL Supplementary Appendix 1. Online search strategies. Supplementary Appendix 2. 